-
Carbon-Ion Radiotherapy, DHODH, and Gastric Cancer
2026-09-21
Wang and Cai report that carbon-ion radiotherapy suppresses gastric cancer growth while reducing DHODH, increasing ferroptosis-associated stress, and promoting M1-like macrophage polarization. The study connects radiation modality, tumor-cell redox biology, and immune-cell behavior, providing a mechanistic basis for investigating DHODH as a modifier of carbon-ion treatment.
-
Ethacridine Lactate Monohydrate in Cell Assays
2026-09-21
Ethacridine lactate monohydrate is a ≥98% pure acridine-derived antiseptic supplied as solid B1749 for scientific research. Its documented solubility and storage profile support controlled use in biochemical and cellular workflows, but the cited YAP-TEAD study does not establish a direct effect of this compound on super-enhancer biology.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-20
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a time-aware framework showing that drug-induced proliferation arrest and cell death can occur together, but in different proportions and on different schedules, with direct implications for assay design and response interpretation.
-
LY294002: A Mechanistic Assay Guide
2026-09-19
LY294002 is more than a PI3K/Akt/mTOR signaling pathway inhibitor: it is a reversible perturbation tool for connecting mitochondrial quality control with inflammatory cell death. This guide translates recent gouty arthritis findings into rigorous assay design, controls, and interpretation.
-
Psoralen-Induced Cholestasis via ERK1/2
2026-09-19
A 2024 Chemical Research in Toxicology study shows that psoralen and isopsoralen can combine estrogen-like activity with ERK1/2 activation to produce cholestatic liver injury in zebrafish larvae. By linking altered bile-acid regulation to increased ERK1/2 phosphorylation and pharmacological rescue by GDC-0994 and exemestane, the work identifies a mechanistic framework for studying phytoestrogen-associated cholestasis.
-
Calpain Inhibitor I, ALLN: Protocol Guide
2026-09-18
Calpain Inhibitor I, ALLN (SKU A2602) provides a practical tool for probing calpain and cathepsin-dependent proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It is a research reagent only; dossier findings should not be treated as diagnostic, therapeutic, or universally predictive evidence.
-
Cefoperazone Sodium Salt: Assay Workflows
2026-09-18
Build reproducible antimicrobial screens, resistance models, and biliary tract infection research workflows with Cefoperazone sodium salt. This guide connects β-lactamase stability, broth microdilution design, comparative benchmarking, and practical troubleshooting.
-
Z-VAD-FMK and the Short IL-18 Caspase-3 Axis
2026-09-17
Z-VAD-FMK is more than a general apoptosis inhibitor: it can help test whether caspase-3-dependent IL-18 processing links tumor-cell death to NK-cell surveillance. This article translates recent mechanistic findings into practical assay and interpretation strategies.
-
Hexose Diphosphate: Metabolic Assay Workflows
2026-09-17
Turn hexose diphosphate into a controlled perturbation tool for glycolytic flux, ischemic stress, and energy homeostasis research. This workflow distinguishes established metabolic applications from hypothesis-driven inflammatory signaling experiments inspired by new phosphoenolpyruvate findings.
-
NAT1–ENO1–Lactate Axis in Colorectal Cancer
2026-09-16
A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator in colorectal cancer, showing that NAT1-dependent acetylation restrains ENO1, lactate production, and PD-L1 stability. The work connects tumor glycolysis to TRAF6 signaling and checkpoint therapy response, providing a mechanistic framework for testing lactate-directed interventions.
-
Repaglinide as a Metabolic Assay Probe in AML
2026-09-15
Repaglinide is examined here as a controlled metabolic perturbation rather than an AML treatment. This article connects its beta-cell pharmacology with new evidence linking energy deficiency, ATG4B localization, PRMT1 activity, and DNA repair while defining practical assay boundaries.
-
ONX-0914 (PR-957): Immunoproteasome Assay Guide
2026-09-15
ONX-0914 (PR-957) enables selective LMP7 inhibition for cytokine, autoimmune-disease, and synaptic-plasticity research. This practical guide connects PBMC assay design with the reference study’s hippocampal findings, emphasizing concentration control, matched vehicles, and orthogonal validation.
-
Magnetic In Vivo CAR-T Mimicry for Solid Tumors
2026-09-14
This Advanced Materials study presents a magnetic bispecific nano-antibody that engages circulating T cells in vivo and redirects them toward solid tumors, creating CAR-T-mimicking effector cells without conventional ex vivo manufacturing. Its combination of CD3 engagement, PD-L1 recognition, and externally guided migration offers a practical strategy for addressing poor tumor infiltration, although translation will require further validation of safety, biodistribution, and magnetic-field control.
-
3X (DYKDDDDK) Peptide: FLAG Workflow Guide
2026-09-14
The 3X (DYKDDDDK) Peptide supports sensitive FLAG-protein capture, competition-based elution, antibody validation, and metal-aware assay development. This practical guide connects routine FLAG workflows with structural and secretory-pathway research, emphasizing controls that prevent calcium, accessibility, and storage artifacts.
-
Paeoniflorin Reprograms Tmem176b+ Macrophages
2026-09-13
A 2025 study used single-cell RNA sequencing and functional perturbation experiments to identify Tmem176b+ macrophages as key mediators of paeoniflorin protection during hepatic ischemia-reperfusion injury. The findings connect macrophage-state transitions with THBS1-CD47 and SPP1-CD44 signaling, offering a mechanistic framework for studying immune cell modulation in liver injury.